The FDA on September 17, 2024, approved KISQALI® with an Aromatase Inhibitor for the adjuvant treatment of adults with Hormone Receptor (HR)-positive, human Epidermal Growth Factor Receptor 2 (HER2)-negative Stage II and III early Breast cancer at high risk of recurrence. Additionally, FDA also approved the KISQALI® and FEMARA® Co-Pack for the same indication. KISQALI® and KISQALI® FEMARA® Co-Pack are products of Novartis Pharmaceuticals Corporation.
Bottom Ad
Advertisement
Subscribe
